Health Dictionary Find a Doctor

Atopic dermatitis

A child with atopic dermatitis

For patient information, click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Shalinder Singh, M.B.B.S.[2] Ogechukwu Hannah Nnabude, MD

Synonyms and keywords: Atopic eczema, Erythrodermic eczema

Overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Shalinder Singh, M.B.B.S.[2] Ogechukwu Hannah Nnabude, MD

Overview

Atopic dermatitis is a chronic inflammatory skin disorder that occurs primarily in children, but also affects adults, usually with a personal or family history of atopy including asthma, and allergic rhinitis. Atopic dermatitis presents usually with intense pruritus and is often associated with elevated levels of immunoglobulin E (IgE).

Historical Perspective

The term atopic dermatitis was first coined by Fred Wise and Marion Sulzberger, American dermatologists, in 1933, and the first widely used diagnostic criteria for atopic dermatitis was published by Jon Hanifin and Georg Rajka, in 1980.

Pathophysiology

Atopic dermatitis is a chronic inflammatory skin disorder with an immunologic background and occurs in patients with a personal or family history of atopy (i.e. asthma or allergic rhinitis). It is caused by either skin barrier dysfunction or immune dysregulation of the adaptive and innate immune response leading to an enhanced IgE-mediated, systemic Th2 response. The skin barrier is invaded by exogenous substances, including allergens, irritants and microbes; and the tightly packed structure of the stratum corneum is further compromised. Systemically, a dysfunctional innate and adaptive immune response causes further damage to the epidermis.

Causes

Atopic dermatitis is the result of either skin barrier dysfunction or immune dysregulation due to genetic defects. The most important genetic defect includes mutations in the filaggrin gene (FLG).

Differentiating Atopic Dermatitis from other Diseases

Atopic dermatitis is a chronic inflammatory skin disorder, which is indistinguishable from other causes of dermatitis. Atopic dermatitis is usually associated with a personal or family history of atopic diseases including asthma, allergic rhinitis and food allergy. The most common clinically similar dermatitis in infancy is seborrheic dermatitis which includes hyperkeratosis of the scalp, also found in atopic dermatitis.

Epidemiology and Demographics

It now affects 10-20% of children and 1-3% of adults in industrialized countries, and its prevalence there has more than doubled in the past thirty years. Atopic dermatitis incidence is highest during infancy and early childhood. The majority of atopic dermatitis patients have onset of symptoms <5 years of age. The prevalence of atopic dermatitis is approximately 5,000-20,000 cases per 100,000 children worldwide. In 2003, the prevalence of atopic dermatitis was estimated to be 10,700 cases per 100,000 children in the United States.

Risk Factors

Atopic dermatitis is a multifactorial, chronic inflammatory skin disease as a result of interactions between various genetic, immune and environmental factors. The most important risk factor for the development of atopic dermatitis is a family history or personal history of atopy including asthma, allergic rhinitis, food allergy.

Screening

There is insufficient evidence to recommend routine screening for atopic dermatitis.

Natural History, Complications and Prognosis

The symptoms of atopic dermatitis usually start during the first few years of life, and present with symptoms such as intense pruritus and chronic and relapsing age dependent eczematous lesions. Common complications of atopic dermatitis include super-infection with staphylococcus aureus, herpes simplex virus, and molluscum contagiosum; sleep problems due to intense pruritus, ocular comorbidities, and topical corticosteroids leading to striae formation.

Diagnosis

Diagnostic Studies

Due to the variable morphology, distribution of skin lesions, and intermittent clinical features, it is very challenging to define the diagnosis of atopic dermatitis. Atopic dermatitis is primarily diagnosed based on the clinical presentation. Currently, the most commonly used criteria worldwide is published by the United Kingdom Working Group and is based upon history, morphology and distribution of eczematous lesions, and clinical features of atopic dermatitis. In patients with atopic dermatitis, to rule out other skin conditions, a histologic examination of a skin biopsy and other laboratory tests (eg, serum immunoglobulin E, potassium hydroxide preparation, patch testing, genetic testing) can be considered.

History and Symptoms

The most common symptoms of atopic dermatitis include pruritus, distribution of rash in age- specific patters and dry skin. Patients often have a personal or family history of asthma or allergic rhinitis. Patients with atopic dermatitis may report a positive history of cutaneous hyper-reactivity to diverse environmental stimuli and atopic disorders.

Physical Examination

Atopic dermatitis is a chronic or relapsing hypersensitive manifestation of the skin. Common physical examination findings of atopic dermatitis include pruritus, eczematous lesions, xerosis and lichenification. The lesions are usually age-specific and can be at various stages of development. The lesions can involve any area of the body in severe cases, but usually, it is uncommon to find lesions in the axillary, gluteal, or groin area.

Laboratory Findings

The diagnosis of atopic dermatitis remains clinical as there is no reliable bio-marker that can differentiate atopic dermatitis from other skin diseases.

Other diagnostic studies

There are no routinely diagnostic studies for atopic dermatitis, but in selected patients to rule out other skin conditions, a histologic examination of a skin biopsy and other laboratory tests (eg, serum immunoglobulin E, potassium hydroxide preparation, patch testing, genetic testing) can be considered.

Treatment

Medical Therapy

The mainstay of treatment for atopic dermatitis depends upon the severity of the disease and is treated with a combination of conservative and medical therapy. The goals of treatment include the elimination of aggravating factors, skin barrier function repair, maintaining skin hydration, and pharmacologic treatment of skin inflammation. Pharmacologic medical therapies for atopic dermatitis can be classified according to several severity scales( (i.e SCORAD index, the Eczema Area, and Severity Index (EASI), and the Patient-Oriented Eczema Measure POEM).

Primary Prevention

Primary prevention applies to patients with a history of other atopic diseases and have not been diagnosed with atopic dermatitis yet. Its primary goal is to reduce the risk of developing atopic dermatitis in the future. Approaches to reduce the development of atopic dermatitis in children usually include the minimization of antibiotics administration in infants and infections in infants.

Secondary prevention

Secondary prevention involves protecting and restoring the epidermal skin barrier function including abstaining from using soap, cosmetics, dyes, fragrances, and detergents, washing new clothes before wearing them, avoiding frequent and sudden climate changes, using air humidifiers in winters, avoiding excessive exposure to UV radiation and using SPF sunscreens, regular application of emollients every 6 hours, and stress-reducing therapy

Financial costs

There has been no discussion on the cost-effectiveness of therapy for atopic dermatitis, however, in a retrospective study, the utilization of health care and treatment costs annually were higher for patients with atopic dermatitis than for controls without atopic dermatitis and was associated with the severity of the disease.

Future or Investigational Therapies

A more novel form of treatment involves exposure to broad or narrow-band ultraviolet light. UV radiation exposure has been found to have a localized immunomodulatory effect on affected tissues, and may be used to decrease the severity and frequency of flares. In particular, Meduri et al. have suggested that the usage of UVA1 is more effective in treating acute flares, whereas narrow-band UVB is more effective in long-term management scenarios. However, UV radiation has also been implicated in various types of skin cancer, and thus UV treatment is not without risk.

Historical Perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ogechukwu Hannah Nnabude, MD; Shalinder Singh, M.B.B.S.[2]

Overview

In 1933, atopic dermatitis was first coined by two American dermatologists, Fred Wise and Marion Sulzberger. The first study on the clinical features of asthma as well as allergic rhinitis and genetics was performed by Cooke and Vander in 1916. An association of higher serum IgE levels was published by Bruno Wüthrich in 1978.

Historical Perspective

Discovery

  • One of the very first traces of the relationship between allergies and genetic factors was described by Hippocrates.[1]
  • In 1816, Willan and Bateman described a disease, “Porrigo larvalis,” which is identified as one of the earliest descriptions of atopic dermatitis.[2][3][4]
  • The first systemic study on the clinical features of asthma as well as allergic rhinitis and genetics was performed by Cooke and Vander in 1916.[5]
  • The association between heritable hypersensitivity to allergens in patients with asthma and hay fever and atopic dermatitis was made in 1923 by Arthur Coca and Robert Cooke.[6][7]
  • The term atopic dermatitis was first coined from the Greek word, atopos, by Fred Wise and Marion Sulzberger, American dermatologists, in 1933. Fred Wise and Marion Sulzberger enhanced Arthur Coca and Robert Cooke’s concept to include the description of atopic dermatitis.[3][8][9][10]
  • A paper reporting a patient with atopic dermatitis was published by Bruno Wüthrich in 1978, demonstrating on average higher serum IgE levels compared with controls.[11]
  • The first widely used diagnostic criteria for atopic dermatitis was published by Jon Hanifin and Georg Rajka, in 1980.[12]
  • Hanifin and Rajka’s criteria was modified by Williams et al. in 1997, to develop the UK Working Party criteria, in which an individual must have itchy skin for 12 months along with other features.[13]
  • In 2006, filaggrin gene mutations were first implicated in the pathogenesis of atopic dermatitis by Palmer et al.[14]

References

  1. Mier, P.D. (1975). “EARLIEST DESCRIPTION OF THE ATOPIC SYNDROME?”. British Journal of Dermatology. 92 (3): 359–359. doi:10.1111/j.1365-2133.1975.tb03091.x. ISSN 0007-0963.
  2. Wallach D, Coste J, Tilles G, Taïeb A (October 2005). “The first images of atopic dermatitis: an attempt at retrospective diagnosis in dermatology”. J. Am. Acad. Dermatol. 53 (4): 684–9. doi:10.1016/j.jaad.2005.06.045. PMID 16198792.
  3. 3.0 3.1 Wallach, Daniel; Taïeb, Alain (2014). “Atopic Dermatitis/Atopic Eczema”. 100: 81–96. doi:10.1159/000358606. ISSN 1660-2242.
  4. Levell, N.J. (2000). “Thomas Bateman MD FLS 1778-1821”. British Journal of Dermatology. 143 (1): 9–15. doi:10.1046/j.1365-2133.2000.03582.x. ISSN 0007-0963.
  5. Dworetzky, Murray; Cohen, Sheldon G.; Blumenthal, Malcolm N. (2002). “Pioneers and milestones”. Journal of Allergy and Clinical Immunology. 110 (4): 674–680. doi:10.1016/S0091-6749(02)70054-7. ISSN 0091-6749.
  6. Kramer, Owen N.; Strom, Mark A.; Ladizinski, Barry; Lio, Peter A. (2017). “The history of atopic dermatitis”. Clinics in Dermatology. 35 (4): 344–348. doi:10.1016/j.clindermatol.2017.03.005. ISSN 0738-081X.
  7. Cohen S, Dworetzky M, Frick OL (2003). “Coca and Cooke on the classification of hypersensitiveness”. J Allergy Clin Immunol. 111 (1): 205–10. PMID 12532128.
  8. Kramer, Owen N.; Strom, Mark A.; Ladizinski, Barry; Lio, Peter A. (2017). “The history of atopic dermatitis”. Clinics in Dermatology. 35 (4): 344–348. doi:10.1016/j.clindermatol.2017.03.005. ISSN 0738-081X.
  9. Hanifin, Jon M. (1982). “Atopic dermatitis”. Journal of the American Academy of Dermatology. 6 (1): 1–13. doi:10.1016/S0190-9622(82)70001-5. ISSN 0190-9622.
  10. Ständer, Sonja; Ropper, Allan H. (2021). “Atopic Dermatitis”. New England Journal of Medicine. 384 (12): 1136–1143. doi:10.1056/NEJMra2023911. ISSN 0028-4793.
  11. Thomsen, Simon F. (2015). “Epidemiology and natural history of atopic diseases”. European Clinical Respiratory Journal. 2 (1): 24642. doi:10.3402/ecrj.v2.24642. ISSN 2001-8525.
  12. . doi:10.2340/00015555924447. Missing or empty |title= (help)
  13. Williams HC, Burney PG, Hay RJ, Archer CB, Shipley MJ, Hunter JJ, Bingham EA, Finlay AY, Pembroke AC, Graham-Brown RA (September 1994). “The U.K. Working Party’s Diagnostic Criteria for Atopic Dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis”. Br. J. Dermatol. 131 (3): 383–96. PMID 7918015.
  14. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, Goudie DR, Sandilands A, Campbell LE, Smith FJ, O’Regan GM, Watson RM, Cecil JE, Bale SJ, Compton JG, DiGiovanna JJ, Fleckman P, Lewis-Jones S, Arseculeratne G, Sergeant A, Munro CS, El Houate B, McElreavey K, Halkjaer LB, Bisgaard H, Mukhopadhyay S, McLean WH (April 2006). “Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis”. Nat. Genet. 38 (4): 441–6. doi:10.1038/ng1767. PMID 16550169.
Pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ogechukwu Hannah Nnabude, MD; Shalinder Singh, M.B.B.S.[2]

Overview

Atopic dermatitis is a chronic inflammatory skin disorder with an immunologic background and occurs in patients with a personal or family history of atopy (i.e. asthma or allergic rhinitis). It is caused by either a skin barrier dysfunction or immune dysregulation of the adaptive and innate immune response leading to an enhanced IgE-mediated, systemic Th2 response. The skin barrier is invaded by exogenous substances, including allergens, irritants and microbes; and the tightly packed structure of the stratum corneum is further compromised. Systemically, a dysfunctional innate and adaptive immune response causes further damage to the epidermis.

Pathophysiology

Physiology

The normal physiology of atopic dermatitis can be understood as follows:

Epidermal barrier function:

Immune response:

Pathogenesis

It is understood that atopic dermatitis is the result of either skin barrier dysfunction or immune dysregulation.[17]

Epidermal barrier dysfunction (outside-in hypothesis):[18]

Immune dysregulation (inside-out’ hypothesis):[29]

  • Innate immune response:
  • Adaptive immune response:
    • Increased allergen penetration through the damaged epidermis leading to a Th2-type milieu is thought to explain the critical link between the barrier defect of atopic dermatitis patients with FLG mutations and Th2 polarization.[33]
    • Enhanced expression of Th2, Th17, and Th22 cytokines, characterize the acute initiation of atopic dermatitis lesions.[34][3]
    • Epidermal barrier function is regulated through Th2 and Th22 cytokines (IL-4, IL-13, IL-31, and IL-22) by:[35][3]
      • Stimulating epidermal hyperplasia
      • Inhibiting the expression of terminal keratinocyte differentiation genes (eg, FLG, loricrin, involucrin)
      • Suppressing the production of AMPs
  • Thymic stromal lymphopoietin:
    • Defective skin barrier and enhanced epidermal protease activity, which is reported in atopic dermatitis, promote TSLP production and Th2 response, leading to atopic dermatitis-like inflammation.[36]
    • TSLP polymorphisms have been linked to the severity of atopic dermatitis.
    • TSLP genetic variants are associated with atopic dermatitis and eczema herpeticum.[37]
    • In patients with defective skin barrier due to FLG mutations, TSLP genetic variants are associated with reduced probability of having persistent atopic dermatitis.[38]

Genetics

Recent studies have established a strong genetic association of atopic dermatitis. Twin studies have indicated high heritability of atopic dermatitis with a concordance rate of 72–86 % for monozygotic twins compared with 21–23 % for dizygotic twins.[39]

Genes involved in the pathogenesis of atopic dermatitis include:[40]

Genes involved in the pathogenesis of atopic dermatitis
Filaggrin Gene mutation
SPINK5 and LEKTI gene
MHC (or HLA) genes
Innate Immune system genes:
Adaptive immune system genes Cytokines and related genes:
Chemokines and related genes:
Drug-metabolizing genes
Other genes
Adapted from Molecular Genetic of Atopic dermatitis: An Update[47]

Associated Conditions

Conditions associated with atopic dermatitis:

Gross Pathology

On gross pathology, characteristic findings of atopic dermatitis include:[48]

  • Acute atopic dermatitis:
  • Chronic atopic dermatitis:
    • Lichenified plaques
    • Prominent skin markings

Microscopic Pathology

On microscopic histopathological analysis, characteristic findings of atopic dermatitis include:[49]

References

  1. Elias PM, Wakefield JS (October 2014). “Mechanisms of abnormal lamellar body secretion and the dysfunctional skin barrier in patients with atopic dermatitis”. J. Allergy Clin. Immunol. 134 (4): 781–791.e1. doi:10.1016/j.jaci.2014.05.048. PMC 4186911. PMID 25131691.
  2. Sandilands A, Sutherland C, Irvine AD, McLean WH (May 2009). “Filaggrin in the frontline: role in skin barrier function and disease”. J. Cell. Sci. 122 (Pt 9): 1285–94. doi:10.1242/jcs.033969. PMC 2721001. PMID 19386895.
  3. 3.0 3.1 3.2 3.3 3.4 Ständer, Sonja; Ropper, Allan H. (2021). “Atopic Dermatitis”. New England Journal of Medicine. 384 (12): 1136–1143. doi:10.1056/NEJMra2023911. ISSN 0028-4793.
  4. Sandilands A, Sutherland C, Irvine AD, McLean WH (May 2009). “Filaggrin in the frontline: role in skin barrier function and disease”. J. Cell. Sci. 122 (Pt 9): 1285–94. doi:10.1242/jcs.033969. PMC 2721001. PMID 19386895.
  5. De Benedetto A, Rafaels NM, McGirt LY, Ivanov AI, Georas SN, Cheadle C, Berger AE, Zhang K, Vidyasagar S, Yoshida T, Boguniewicz M, Hata T, Schneider LC, Hanifin JM, Gallo RL, Novak N, Weidinger S, Beaty TH, Leung DY, Barnes KC, Beck LA (March 2011). “Tight junction defects in patients with atopic dermatitis”. J. Allergy Clin. Immunol. 127 (3): 773–86.e1–7. doi:10.1016/j.jaci.2010.10.018. PMC 3049863. PMID 21163515.
  6. Broccardo CJ, Mahaffey S, Schwarz J, Wruck L, David G, Schlievert PM, Reisdorph NA, Leung DY (January 2011). “Comparative proteomic profiling of patients with atopic dermatitis based on history of eczema herpeticum infection and Staphylococcus aureus colonization”. J. Allergy Clin. Immunol. 127 (1): 186–93, 193.e1–11. doi:10.1016/j.jaci.2010.10.033. PMC 3059191. PMID 21211653.
  7. 7.0 7.1 Barnes KC (January 2010). “An update on the genetics of atopic dermatitis: scratching the surface in 2009”. J. Allergy Clin. Immunol. 125 (1): 16–29.e1–11, quiz 30–1. doi:10.1016/j.jaci.2009.11.008. PMC 2874322. PMID 20109730.
  8. Kuo IH, Yoshida T, De Benedetto A, Beck LA (February 2013). “The cutaneous innate immune response in patients with atopic dermatitis”. J. Allergy Clin. Immunol. 131 (2): 266–78. doi:10.1016/j.jaci.2012.12.1563. PMID 23374259.
  9. Cario E, Gerken G, Podolsky DK (July 2004). “Toll-like receptor 2 enhances ZO-1-associated intestinal epithelial barrier integrity via protein kinase C”. Gastroenterology. 127 (1): 224–38. PMID 15236188.
  10. Kuo IH, Yoshida T, De Benedetto A, Beck LA (February 2013). “The cutaneous innate immune response in patients with atopic dermatitis”. J. Allergy Clin. Immunol. 131 (2): 266–78. doi:10.1016/j.jaci.2012.12.1563. PMID 23374259.
  11. Kuo IH, Carpenter-Mendini A, Yoshida T, McGirt LY, Ivanov AI, Barnes KC, Gallo RL, Borkowski AW, Yamasaki K, Leung DY, Georas SN, De Benedetto A, Beck LA (April 2013). “Activation of epidermal toll-like receptor 2 enhances tight junction function: implications for atopic dermatitis and skin barrier repair”. J. Invest. Dermatol. 133 (4): 988–98. doi:10.1038/jid.2012.437. PMC 3600383. PMID 23223142.
  12. Lynch SV, Pedersen O (December 2016). “The Human Intestinal Microbiome in Health and Disease”. N. Engl. J. Med. 375 (24): 2369–2379. doi:10.1056/NEJMra1600266. PMID 27974040.
  13. De Benedetto A, Agnihothri R, McGirt LY, Bankova LG, Beck LA (January 2009). “Atopic dermatitis: a disease caused by innate immune defects?”. J. Invest. Dermatol. 129 (1): 14–30. doi:10.1038/jid.2008.259. PMID 19078985.
  14. Liu YJ (February 2006). “Thymic stromal lymphopoietin: master switch for allergic inflammation”. J. Exp. Med. 203 (2): 269–73. doi:10.1084/jem.20051745. PMC 2118215. PMID 16432252.
  15. Takai T (March 2012). “TSLP expression: cellular sources, triggers, and regulatory mechanisms”. Allergol Int. 61 (1): 3–17. doi:10.2332/allergolint.11-RAI-0395. PMID 22270071.
  16. Liu YJ (February 2006). “Thymic stromal lymphopoietin: master switch for allergic inflammation”. J. Exp. Med. 203 (2): 269–73. doi:10.1084/jem.20051745. PMC 2118215. PMID 16432252.
  17. Boguniewicz M, Leung DY (July 2011). “Atopic dermatitis: a disease of altered skin barrier and immune dysregulation”. Immunol. Rev. 242 (1): 233–46. doi:10.1111/j.1600-065X.2011.01027.x. PMC 3122139. PMID 21682749.
  18. Elias PM, Hatano Y, Williams ML (June 2008). “Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms”. J. Allergy Clin. Immunol. 121 (6): 1337–43. doi:10.1016/j.jaci.2008.01.022. PMC 2706021. PMID 18329087.
  19. Morizane S, Yamasaki K, Kajita A, Ikeda K, Zhan M, Aoyama Y, Gallo RL, Iwatsuki K (July 2012). “TH2 cytokines increase kallikrein 7 expression and function in patients with atopic dermatitis”. J. Allergy Clin. Immunol. 130 (1): 259–61.e1. doi:10.1016/j.jaci.2012.03.006. PMC 3387356. PMID 22521249.
  20. Margolis DJ, Apter AJ, Gupta J, Hoffstad O, Papadopoulos M, Campbell LE, Sandilands A, McLean WH, Rebbeck TR, Mitra N (October 2012). “The persistence of atopic dermatitis and filaggrin (FLG) mutations in a US longitudinal cohort”. J. Allergy Clin. Immunol. 130 (4): 912–7. doi:10.1016/j.jaci.2012.07.008. PMC 3462287. PMID 22951058.
  21. McAleer MA, Irvine AD (February 2013). “The multifunctional role of filaggrin in allergic skin disease”. J. Allergy Clin. Immunol. 131 (2): 280–91. doi:10.1016/j.jaci.2012.12.668. PMID 23374260.
  22. Howell MD, Kim BE, Gao P, Grant AV, Boguniewicz M, DeBenedetto A, Schneider L, Beck LA, Barnes KC, Leung DY (September 2009). “Cytokine modulation of atopic dermatitis filaggrin skin expression”. J. Allergy Clin. Immunol. 124 (3 Suppl 2): R7–R12. doi:10.1016/j.jaci.2009.07.012. PMID 19720210.
  23. De Benedetto A, Rafaels NM, McGirt LY, Ivanov AI, Georas SN, Cheadle C, Berger AE, Zhang K, Vidyasagar S, Yoshida T, Boguniewicz M, Hata T, Schneider LC, Hanifin JM, Gallo RL, Novak N, Weidinger S, Beaty TH, Leung DY, Barnes KC, Beck LA (March 2011). “Tight junction defects in patients with atopic dermatitis”. J. Allergy Clin. Immunol. 127 (3): 773–86.e1–7. doi:10.1016/j.jaci.2010.10.018. PMC 3049863. PMID 21163515.
  24. Elias PM, Hatano Y, Williams ML (June 2008). “Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms”. J. Allergy Clin. Immunol. 121 (6): 1337–43. doi:10.1016/j.jaci.2008.01.022. PMC 2706021. PMID 18329087.
  25. Cork MJ, Robinson DA, Vasilopoulos Y, Ferguson A, Moustafa M, MacGowan A, Duff GW, Ward SJ, Tazi-Ahnini R (July 2006). “New perspectives on epidermal barrier dysfunction in atopic dermatitis: gene-environment interactions”. J. Allergy Clin. Immunol. 118 (1): 3–21, quiz 22–3. doi:10.1016/j.jaci.2006.04.042. PMID 16815133.
  26. Leung DY (June 2013). “New insights into atopic dermatitis: role of skin barrier and immune dysregulation”. Allergol Int. 62 (2): 151–61. doi:10.2332/allergolint.13-RAI-0564. PMID 23712284.
  27. Cork MJ, Danby SG, Vasilopoulos Y, Hadgraft J, Lane ME, Moustafa M; et al. (2009). “Epidermal barrier dysfunction in atopic dermatitis”. J Invest Dermatol. 129 (8): 1892–908. doi:10.1038/jid.2009.133. PMID 19494826.
  28. Flohr C, England K, Radulovic S, McLean WH, Campbel LE, Barker J, Perkin M, Lack G (December 2010). “Filaggrin loss-of-function mutations are associated with early-onset eczema, eczema severity and transepidermal water loss at 3 months of age”. Br. J. Dermatol. 163 (6): 1333–6. PMID 21137118.
  29. Elias PM, Hatano Y, Williams ML (June 2008). “Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms”. J. Allergy Clin. Immunol. 121 (6): 1337–43. doi:10.1016/j.jaci.2008.01.022. PMC 2706021. PMID 18329087.
  30. Kuo IH, Carpenter-Mendini A, Yoshida T, McGirt LY, Ivanov AI, Barnes KC, Gallo RL, Borkowski AW, Yamasaki K, Leung DY, Georas SN, De Benedetto A, Beck LA (April 2013). “Activation of epidermal toll-like receptor 2 enhances tight junction function: implications for atopic dermatitis and skin barrier repair”. J. Invest. Dermatol. 133 (4): 988–98. doi:10.1038/jid.2012.437. PMC 3600383. PMID 23223142.
  31. Kong HH, Oh J, Deming C, Conlan S, Grice EA, Beatson MA, Nomicos E, Polley EC, Komarow HD, Murray PR, Turner ML, Segre JA (May 2012). “Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis”. Genome Res. 22 (5): 850–9. doi:10.1101/gr.131029.111. PMC 3337431. PMID 22310478.
  32. Macias ES, Pereira FA, Rietkerk W, Safai B (March 2011). “Superantigens in dermatology”. J. Am. Acad. Dermatol. 64 (3): 455–72, quiz 473–4. doi:10.1016/j.jaad.2010.03.044. PMID 21315950.
  33. Boguniewicz M, Leung DY (July 2011). “Atopic dermatitis: a disease of altered skin barrier and immune dysregulation”. Immunol. Rev. 242 (1): 233–46. doi:10.1111/j.1600-065X.2011.01027.x. PMC 3122139. PMID 21682749.
  34. Leung DY, Guttman-Yassky E (October 2014). “Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches”. J. Allergy Clin. Immunol. 134 (4): 769–79. doi:10.1016/j.jaci.2014.08.008. PMC 4186710. PMID 25282559.
  35. Leung DY, Guttman-Yassky E (October 2014). “Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches”. J. Allergy Clin. Immunol. 134 (4): 769–79. doi:10.1016/j.jaci.2014.08.008. PMC 4186710. PMID 25282559.
  36. Takai T (March 2012). “TSLP expression: cellular sources, triggers, and regulatory mechanisms”. Allergol Int. 61 (1): 3–17. doi:10.2332/allergolint.11-RAI-0395. PMID 22270071.
  37. Gao PS, Rafaels NM, Mu D, Hand T, Murray T, Boguniewicz M, Hata T, Schneider L, Hanifin JM, Gallo RL, Gao L, Beaty TH, Beck LA, Leung DY, Barnes KC (June 2010). “Genetic variants in thymic stromal lymphopoietin are associated with atopic dermatitis and eczema herpeticum”. J. Allergy Clin. Immunol. 125 (6): 1403–1407.e4. doi:10.1016/j.jaci.2010.03.016. PMC 2925504. PMID 20466416.
  38. Margolis DJ, Kim B, Apter AJ, Gupta J, Hoffstad O, Papadopoulos M, Mitra N (March 2014). “Thymic stromal lymphopoietin variation, filaggrin loss of function, and the persistence of atopic dermatitis”. JAMA Dermatol. 150 (3): 254–9. doi:10.1001/jamadermatol.2013.7954. PMC 4414492. PMID 24401911.
  39. Al-Shobaili HA, Ahmed AA, Alnomair N, Alobead ZA, Rasheed Z (January 2016). “Molecular Genetic of Atopic dermatitis: An Update”. Int J Health Sci (Qassim). 10 (1): 96–120. PMC 4791162. PMID 27004062.
  40. Al-Shobaili HA, Ahmed AA, Alnomair N, Alobead ZA, Rasheed Z (January 2016). “Molecular Genetic of Atopic dermatitis: An Update”. Int J Health Sci (Qassim). 10 (1): 96–120. PMC 4791162. PMID 27004062.
  41. Irvine AD, McLean WH, Leung DY (October 2011). “Filaggrin mutations associated with skin and allergic diseases”. N. Engl. J. Med. 365 (14): 1315–27. doi:10.1056/NEJMra1011040. PMID 21991953.
  42. Liao H, Waters AJ, Goudie DR, Aitken DA, Graham G, Smith FJ, Lewis-Jones S, McLean WH (December 2007). “Filaggrin mutations are genetic modifying factors exacerbating X-linked ichthyosis”. J. Invest. Dermatol. 127 (12): 2795–8. doi:10.1038/sj.jid.5700971. PMID 17657246.
  43. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, Goudie DR, Sandilands A, Campbell LE, Smith FJ, O’Regan GM, Watson RM, Cecil JE, Bale SJ, Compton JG, DiGiovanna JJ, Fleckman P, Lewis-Jones S, Arseculeratne G, Sergeant A, Munro CS, El Houate B, McElreavey K, Halkjaer LB, Bisgaard H, Mukhopadhyay S, McLean WH (April 2006). “Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis”. Nat. Genet. 38 (4): 441–6. doi:10.1038/ng1767. PMID 16550169.
  44. Rupnik H, Rijavec M, Korošec P (February 2015). “Filaggrin loss-of-function mutations are not associated with atopic dermatitis that develops in late childhood or adulthood”. Br. J. Dermatol. 172 (2): 455–61. doi:10.1111/bjd.13477. PMID 25314673.
  45. Al-Shobaili HA, Ahmed AA, Alnomair N, Alobead ZA, Rasheed Z (January 2016). “Molecular Genetic of Atopic dermatitis: An Update”. Int J Health Sci (Qassim). 10 (1): 96–120. PMC 4791162. PMID 27004062.
  46. Cork MJ, Robinson DA, Vasilopoulos Y, Ferguson A, Moustafa M, MacGowan A, Duff GW, Ward SJ, Tazi-Ahnini R (July 2006). “New perspectives on epidermal barrier dysfunction in atopic dermatitis: gene-environment interactions”. J. Allergy Clin. Immunol. 118 (1): 3–21, quiz 22–3. doi:10.1016/j.jaci.2006.04.042. PMID 16815133.
  47. Al-Shobaili HA, Ahmed AA, Alnomair N, Alobead ZA, Rasheed Z (January 2016). “Molecular Genetic of Atopic dermatitis: An Update”. Int J Health Sci (Qassim). 10 (1): 96–120. PMC 4791162. PMID 27004062.
  48. Mihm, Martin C; Soter, Nicholas A; Dvorak, Harold F; Austen, K Frank (1976). “The Structure Of Normal Skin And The Morphology Of Atopic Eczema”. Journal of Investigative Dermatology. 67 (3): 305–312. doi:10.1111/1523-1747.ep12514346. ISSN 0022-202X.
  49. Mihm, Martin C; Soter, Nicholas A; Dvorak, Harold F; Austen, K Frank (1976). “The Structure Of Normal Skin And The Morphology Of Atopic Eczema”. Journal of Investigative Dermatology. 67 (3): 305–312. doi:10.1111/1523-1747.ep12514346. ISSN 0022-202X.
Causes

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ogechukwu Hannah Nnabude, MD; Shalinder Singh, M.B.B.S.[2]

Overview

Atopic dermatitis (AD) is a chronic inflammatory skin disorder which primarily occurs as a result of various genetics, immune or environmental factors. Other causes leading to development or aggravation of atopic dermatitis include infection, hygiene hypothesis, climate and cigarette smoking.

Causes

Common Causes

Causes by Organ System

Cardiovascular No underlying causes
Chemical/Poisoning No underlying causes
Dental No underlying causes
Dermatologic No underlying causes
Drug Side Effect No underlying causes
Ear Nose Throat No underlying causes
Endocrine No underlying causes
Environmental No underlying causes
Gastroenterologic No underlying causes
Genetic Filaggrin gene mutation
Hematologic No underlying causes
Iatrogenic No underlying causes
Infectious Disease Colonization by staphylococcus aureus and herpes simplex virus.
Musculoskeletal/Orthopedic No underlying causes
Neurologic No underlying causes
Nutritional/Metabolic No underlying causes
Obstetric/Gynecologic No underlying causes
Oncologic No underlying causes
Ophthalmologic No underlying causes
Overdose/Toxicity No underlying causes
Psychiatric No underlying causes
Pulmonary No underlying causes
Renal/Electrolyte No underlying causes
Rheumatology/Immunology/Allergy No underlying causes
Sexual No underlying causes
Trauma No underlying causes
Urologic No underlying causes
Miscellaneous No underlying causes

Causes in Alphabetical Order

List the causes of the disease in alphabetical order:

References

  1. Paternoster L, Standl M, Chen CM, Ramasamy A, Bønnelykke K, Duijts L, Ferreira MA, Alves AC, Thyssen JP, Albrecht E, Baurecht H, Feenstra B, Sleiman PM, Hysi P, Warrington NM, Curjuric I, Myhre R, Curtin JA, Groen-Blokhuis MM, Kerkhof M, Sääf A, Franke A, Ellinghaus D, Fölster-Holst R, Dermitzakis E, Montgomery SB, Prokisch H, Heim K, Hartikainen AL, Pouta A, Pekkanen J, Blakemore AI, Buxton JL, Kaakinen M, Duffy DL, Madden PA, Heath AC, Montgomery GW, Thompson PJ, Matheson MC, Le Souëf P, St Pourcain B, Smith GD, Henderson J, Kemp JP, Timpson NJ, Deloukas P, Ring SM, Wichmann HE, Müller-Nurasyid M, Novak N, Klopp N, Rodríguez E, McArdle W, Linneberg A, Menné T, Nohr EA, Hofman A, Uitterlinden AG, van Duijn CM, Rivadeneira F, de Jongste JC, van der Valk RJ, Wjst M, Jogi R, Geller F, Boyd HA, Murray JC, Kim C, Mentch F, March M, Mangino M, Spector TD, Bataille V, Pennell CE, Holt PG, Sly P, Tiesler CM, Thiering E, Illig T, Imboden M, Nystad W, Simpson A, Hottenga JJ, Postma D, Koppelman GH, Smit HA, Söderhäll C, Chawes B, Kreiner-Møller E, Bisgaard H, Melén E, Boomsma DI, Custovic A, Jacobsson B, Probst-Hensch NM, Palmer LJ, Glass D, Hakonarson H, Melbye M, Jarvis DL, Jaddoe VW, Gieger C, Strachan DP, Martin NG, Jarvelin MR, Heinrich J, Evans DM, Weidinger S (December 2011). “Meta-analysis of genome-wide association studies identifies three new risk loci for atopic dermatitis”. Nat. Genet. 44 (2): 187–92. doi:10.1038/ng.1017. PMC 3272375. PMID 22197932.
  2. 2.0 2.1 Ständer, Sonja; Ropper, Allan H. (2021). “Atopic Dermatitis”. New England Journal of Medicine. 384 (12): 1136–1143. doi:10.1056/NEJMra2023911. ISSN 0028-4793.


Differentiating Atopic Dermatitis from other Diseases

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ogechukwu Hannah Nnabude, MD; Shalinder Singh, M.B.B.S.[2]

Overview

Atopic dermatitis is a chronic inflammatory skin disorder, which is indistinguishable from other causes of dermatitis. Atopic dermatitis is usually associated with personal or family history of atopic diseases including asthma, allergic rhinitis and food allergy. The most common clinically similar dermatitis in infancy is seborrheic dermatitis which includes hyperkeratosis of the scalp, also found in atopic dermatitis.

Atopic Dermatitis from other Diseases

Atopic dermatitis should be differentiated from allergic contact dermatitis, iirritant contact dermatitis, seborrheic dermatitis, psoriasis, lichen simplex chronicus, ichthyosis vulgaris, nummular dermatitis (discoid eczema), netherton’s syndrome, and dermatitis herpetiformis

Category Diseases Etiology Inherited Acquired Clinical manifestations Para-clinical findings Associated factors
Demography Symptoms Physical examination
Lab Findings Histopathology
Appearance Itching Fever Tenderness Other Eosinophils Serum IgE
Single/

Multiple

Rash Involved areas Pustule
Skin disorders Atopic dermatitis
  • Epidermal barrier dysfunction
  • Immune dysregulation
+ + Multiple
  • Young children –Scalp, cheeks amd extensor surface
  • Adolescents -flexural areas and buttock-thigh creases
  • Adults – facial involvement and skin flexures
+
  • Infra-auricular and retro-auricular fissuring
  • Nipple eczema
  • White dermographism
  • Perifollicular accentuation
Nl to ↑

(Eosinophilia)

  • Epidermal psoriasiform hyperplasia
  • Marked intercellular edema with spongiotic vesiculation
Allergic contact dermatitis[1] + Any May be multiple after 1-2 days of exposure Erythematous well-demarcated papules Surrounding the area in contact with the offending agent + + Nl to ↑

(Eosinophilia)

Nl
Irritant contact dermatitis[2] + Any, more with occupational exposure Usually single immediately after the exposure Well-demarcated red patch with a glazed surface Any area in contact with the irritant + + Nl Nl
  • Cumulative exposure to irritants
  • Negative hypersensitivity tests
Seborrheic dermatitis
  • Not known
+ Any, onset during the infancy and peak during 3rd-4th decades Multiple
  • Cradle cap – yellowish scales on the scalp
  • Patchy or diffuse greasy scaling with or without a yellow-red base
  • Crusts
Scalp, face, trunk, postauricular, diaper area and axilla + +
  • Infants:
    • Cradle cap (Sclap) – non-inflammatory greasy scales on the scalp
    • Asymptomatic
    • Self resolving
Nl Nl Risk factors include

Generalized seborrheic erythroderma in immunodeficient patients

Psoriasis + + Any, 2 peaks of onset 30-39 years and 50-59 years Multiple Well-circumscribed, pink papules and symmetrically distributed cutaneous plaques with silvery scales
  • Scalp
  • Trunk
  • Gluteal cleft
  • Extensor surface of elbows and knees
+ + _ + Nl Nl Risk factors include
Lichen simplex [3]chronicus + Any, peak at 30-50 years of age Multiple Lichenified and erythematous, pruritic exudative plaque, and excoriations Scalp, head, neck, hands, arms, and genitals areas +
  • Color of plaque varies from yellow to reddish-brown
  • Plaque size can vary between 3X6 cm 6X10 cm areas.
Nl Nl Risk factors include
Ichthyosis vulgaris[4] + + Usually in infancy Multiple
  • Extensor surfaces of the extremities
  • Scalp
  • Trunk
  • Scales can vary from mild scaling to large, plate (armor)-like scales and thickening of the skin.
Nl Nl
Nummular dermatitis (discoid eczema) Unknown + Any, two peaks, 6th-7th decade of life in males and 2nd-3rd decade of life in females Multiple
  • Symmetrical coin-shaped erythematous plaques
  • Erosions and excoriations
  • Chronic lesions- central clearing leading to annular lesions
  • Upper and lower extremities
  • Lower trunk
+
  • Chronically lesions result into central clearing leading to annular lesions.
Nl Nl
Netherton’s syndrome[5] Autosomal recessive mutations in the serine protease inhibitor of Kazal type 5 gene (SPINK5), encoding LEKTI, a serine protease inhibitor + Affects neonates Multiple
  • Classic triad
    • Congenital ichthyosiform erythroderma
    • Trichorrhexis invaginata
    • Allergic diseases with ↑ serum IgE levels
  • Ichthyosis linearis circumflexa (ILC) – serpiginous plaques with double scale at the margins
  • Diffuse pattern
  • Axillae,
  • Hair
  • Inguinal folds
  • Gluteal cleft
  • Groin
  • Lower legs
+ +
  • Trichorrhexis invaginata (hair involvement):
    • Sparse, short, spike and brittle
    • “Bamboo hair” or “ball and socket deformity” of hair and eyebrows
    • Nodes along the hair shaft
Nl to ↑

(Eosinophilia)

Diseases Etiology Inherited Acquired Demography Single/

Multiple

Rash Involved areas Pustule Itching Fever Tenderness Other WBC Serum IgE Histopathology Associated factors
Infection Molluscum contagiosum Molluscum contagiosum virus inoculation through direct skin contact + Any, peak among children >5 years of age and young adults Multiple
  • Flesh-colored, dome-shaped papules with a central umbilication
  • Lesions are 2-5mm in diameter
+ If molluscum contagiosum is acquired as sexually transmitted disease, it involves, groin and genital region. Nl Nl
Immunologic disorders Dermatitis herpetiformis[6] Autoimmune disorder as a result of gluten sensitivity leading to the formation of IgA antibodies + Any, mean age of disease onset is 2nd-4th decade Multiple
  • Excoriated papules, plaques and vesicles arranged in a clustered fashion
  • Symmetrical
  • Erosions and excoriations
  • Extensor surfaces including arms, knees, and buttocks.
+
  • Oral manifestation such as vesicles and erosion may be present
Nl Nl
Immune deficiency Wiskott-Aldrich syndrome[7] + Seen almost exclusively in males in infancy Multiple Rash can involve lesions located at the same areas of classical atopic dermatitis:

extensor surfaces of extremities and cheeks or scalp

+ Infants can present with petechiae, prolonged bleeding from umbilicus or circumcision, purpura,hematemesis, melena, epistaxis, hematuria or unusal bruising Nl to ↑

(Eosinophilia)

  • Epidermal psoriasiform hyperplasia
  • Marked intercellular edema with spongiotic vesiculation
Hyper-IgE syndrome[8] + Rare, begin in infancy Multiple
  • Face and scalp
  • Upper trunk and shoulders
  • Buttocks
  • Area behind the ears and around the hairline
+ +
  • Characteristic coarse facies
  • Increased alar width and broad nasal bridge
  • High-arched oral palate
  • Hyperextensible joints
Nl to ↑

(Eosinophilia)

  • Eosinophil-rich infiltration around the hair follicles
Malignancy Mycosis fungoides Clonal expansion of CD4+ memory T cells (CD45RO+) + Mean age is 55- 60 years Multiple
  • Asymmetrical
  • Hips, groin and trunk
+ Nl Nl

References

  1. Nosbaum A, Vocanson M, Rozieres A, Hennino A, Nicolas JF (2009). “Allergic and irritant contact dermatitis”. Eur J Dermatol. 19 (4): 325–32. doi:10.1684/ejd.2009.0686. PMID 19447733.
  2. Bains SN, Nash P, Fonacier L (October 2018). “Irritant Contact Dermatitis”. Clin Rev Allergy Immunol. doi:10.1007/s12016-018-8713-0. PMID 30293200.
  3. Voicu C, Tebeica T, Zanardelli M, Mangarov H, Lotti T, Wollina U, Lotti J, França K, Batashki A, Tchernev G (July 2017). “Lichen Simplex Chronicus as an Essential Part of the Dermatologic Masquerade”. Open Access Maced J Med Sci. 5 (4): 556–557. doi:10.3889/oamjms.2017.133. PMC 5535688. PMID 28785363.
  4. Thyssen JP, Godoy-Gijon E, Elias PM (June 2013). “Ichthyosis vulgaris: the filaggrin mutation disease”. Br. J. Dermatol. 168 (6): 1155–66. doi:10.1111/bjd.12219. PMID 23301728.
  5. Chavanas S, Bodemer C, Rochat A, Hamel-Teillac D, Ali M, Irvine AD, Bonafé JL, Wilkinson J, Taïeb A, Barrandon Y, Harper JI, de Prost Y, Hovnanian A (June 2000). “Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome”. Nat. Genet. 25 (2): 141–2. doi:10.1038/75977. PMID 10835624.
  6. Kárpáti S (2012). “Dermatitis herpetiformis”. Clin. Dermatol. 30 (1): 56–9. doi:10.1016/j.clindermatol.2011.03.010. PMID 22137227.
  7. Buchbinder D, Nugent DJ, Fillipovich AH (2014). “Wiskott-Aldrich syndrome: diagnosis, current management, and emerging treatments”. Appl Clin Genet. 7: 55–66. doi:10.2147/TACG.S58444. PMC 4012343. PMID 24817816.
  8. Mogensen TH (April 2013). “STAT3 and the Hyper-IgE syndrome: Clinical presentation, genetic origin, pathogenesis, novel findings and remaining uncertainties”. JAKSTAT. 2 (2): e23435. doi:10.4161/jkst.23435. PMC 3710320. PMID 24058807.
Risk Factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ogechukwu Hannah Nnabude, MD; Shalinder Singh, M.B.B.S.[2]

Overview

Atopic dermatitis is a multifactorial, chronic inflammatory skin disease as a result of interactions between various genetic, immune, and environmental factors. The most important risk factor for the development of atopic dermatitis is a family history or personal history of atopy including asthma, allergic rhinitis, food allergy.

Risk Factors

The most potent risk factor in the development of atopic dermatitis is a family history or personal history of atopy.

Common Risk Factors

  • Common risk factors in the development of atopic dermatitis include:
    • Family history of atopic dermatitis or other atopy[1]
      • 70% of atopic dermatitis patients have a positive family history of atopic diseases
      • Risk of developing atopic dermatitis is 2- to 3-fold higher in children with 1 atopic parent [2]
      • Risk of developing atopic dermatitis is 3- to 5-fold higher in children with both atopic parents [3]
    • Loss of function mutations in the filaggrin (FLG) gene[4]
      • Risk for earlier-onset atopic dermatitis
      • Risk for severe and persistent atopic dermatitis
    • Personal history of atopy (asthma, allergic rhinitis, food allergy) [5]
    • Environmental factors predisposing individuals to the development of atopic dermatitis include:[6]
      • Temperature (colder climates with low humidity)
      • Ultraviolet radiation
      • Air pollution
      • Water hardness
      • Household hygiene

Less Common Risk Factors

References

  1. Wen HJ, Chen PC, Chiang TL, Lin SJ, Chuang YL, Guo YL (November 2009). “Predicting risk for early infantile atopic dermatitis by hereditary and environmental factors”. Br. J. Dermatol. 161 (5): 1166–72. doi:10.1111/j.1365-2133.2009.09412.x. PMID 19785611.
  2. Küster W, Petersen M, Christophers E, Goos M, Sterry W (1990). “A family study of atopic dermatitis. Clinical and genetic characteristics of 188 patients and 2,151 family members”. Arch. Dermatol. Res. 282 (2): 98–102. PMID 2353830.
  3. Küster W, Petersen M, Christophers E, Goos M, Sterry W (1990). “A family study of atopic dermatitis. Clinical and genetic characteristics of 188 patients and 2,151 family members”. Arch. Dermatol. Res. 282 (2): 98–102. PMID 2353830.
  4. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, Goudie DR, Sandilands A, Campbell LE, Smith FJ, O’Regan GM, Watson RM, Cecil JE, Bale SJ, Compton JG, DiGiovanna JJ, Fleckman P, Lewis-Jones S, Arseculeratne G, Sergeant A, Munro CS, El Houate B, McElreavey K, Halkjaer LB, Bisgaard H, Mukhopadhyay S, McLean WH (April 2006). “Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis”. Nat. Genet. 38 (4): 441–6. doi:10.1038/ng1767. PMID 16550169.
  5. Suh KY (June 2010). “Food allergy and atopic dermatitis: separating fact from fiction”. Semin Cutan Med Surg. 29 (2): 72–8. doi:10.1016/j.sder.2010.03.007. PMID 20579595.
  6. Garmhausen D, Hagemann T, Bieber T, Dimitriou I, Fimmers R, Diepgen T, Novak N (April 2013). “Characterization of different courses of atopic dermatitis in adolescent and adult patients”. Allergy. 68 (4): 498–506. doi:10.1111/all.12112. PMID 23452057.
  7. McKeever TM, Lewis SA, Smith C, Collins J, Heatlie H, Frischer M, Hubbard R (January 2002). “Early exposure to infections and antibiotics and the incidence of allergic disease: a birth cohort study with the West Midlands General Practice Research Database”. J. Allergy Clin. Immunol. 109 (1): 43–50. PMID 11799364.
  8. McKeever TM, Lewis SA, Smith C, Hubbard R (September 2002). “The importance of prenatal exposures on the development of allergic disease: a birth cohort study using the West Midlands General Practice Database”. Am. J. Respir. Crit. Care Med. 166 (6): 827–32. doi:10.1164/rccm.200202-158OC. PMID 12231492.
  9. Wen HJ, Chen PC, Chiang TL, Lin SJ, Chuang YL, Guo YL (November 2009). “Predicting risk for early infantile atopic dermatitis by hereditary and environmental factors”. Br. J. Dermatol. 161 (5): 1166–72. doi:10.1111/j.1365-2133.2009.09412.x. PMID 19785611.
  10. Martignon G, Oryszczyn MP, Annesi-Maesano I (May 2005). “Does childhood immunization against infectious diseases protect from the development of atopic disease?”. Pediatr Allergy Immunol. 16 (3): 193–200. doi:10.1111/j.1399-3038.2005.00254.x. PMID 15853947.
  11. Perkin MR, Craven J, Logan K, Strachan D, Marrs T, Radulovic S, Campbell LE, MacCallum SF, McLean WH, Lack G, Flohr C (August 2016). “Association between domestic water hardness, chlorine, and atopic dermatitis risk in early life: A population-based cross-sectional study”. J. Allergy Clin. Immunol. 138 (2): 509–16. doi:10.1016/j.jaci.2016.03.031. PMID 27241890.
  12. Weber AS, Haidinger G (November 2010). “The prevalence of atopic dermatitis in children is influenced by their parents’ education: results of two cross-sectional studies conducted in Upper Austria”. Pediatr Allergy Immunol. 21 (7): 1028–35. doi:10.1111/j.1399-3038.2010.01030.x. PMID 20444159.
  13. Schram ME, Tedja AM, Spijker R, Bos JD, Williams HC, Spuls PI (May 2010). “Is there a rural/urban gradient in the prevalence of eczema? A systematic review”. Br. J. Dermatol. 162 (5): 964–73. doi:10.1111/j.1365-2133.2010.09689.x. PMID 20331459.
  14. Tsakok T, McKeever TM, Yeo L, Flohr C (November 2013). “Does early life exposure to antibiotics increase the risk of eczema? A systematic review”. Br. J. Dermatol. 169 (5): 983–91. doi:10.1111/bjd.12476. PMID 23782060.
  15. Kantor R, Kim A, Thyssen JP, Silverberg JI (December 2016). “Association of atopic dermatitis with smoking: A systematic review and meta-analysis”. J. Am. Acad. Dermatol. 75 (6): 1119–1125.e1. doi:10.1016/j.jaad.2016.07.017. PMC 5216172. PMID 27542586.
  16. Arndt J, Smith N, Tausk F (July 2008). “Stress and atopic dermatitis”. Curr Allergy Asthma Rep. 8 (4): 312–7. PMID 18606083.
Screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ogechukwu Hannah Nnabude, MD; Shalinder Singh, M.B.B.S.[2]

Overview

There is insufficient evidence to recommend routine screening for atopic dermatitis.

Screening

There is insufficient evidence to recommend routine screening for atopic dermatitis.

Natural History, Complications and Prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ogechukwu Hannah Nnabude, MD; Shalinder Singh, M.B.B.S.[2]

Overview

The symptoms of atopic dermatitis usually start during the first few years of life, and present as intense pruritus and chronic and relapsing age dependent eczematous lesions. Common complications of atopic dermatitis include super-infection with staphylococcus aureus, herpes simplex virus, and molluscum contagiosum; sleep problems due to intense pruritus, ocular comorbidities, and striae formation due to long term use of topical corticosteroids.

Natural History, Complications, and Prognosis

Natural History

  • The symptoms of atopic dermatitis usually start during the first few years of life, and present as intense pruritus and chronic and relapsing age dependent eczematous lesions.[1]
  • The majority of infants and children with atopic dermatitis usually grow out of the disease during childhood.[2]
  • In severe cases, atopic dermatitis continues or relapses in adulthood.[3]
  • The natural history of atopic dermatitis can be categorized into various subtypes according to the clinical features.
    • The most common subtype was characterized by the early onset of atopic dermatitis (<2 years) and persistent until adulthood.[4]
  • In the sequence of atopy march diseases, atopic dermatitis is the first to commence during infancy, followed by allergic rhinitis, food allergy and asthma later in life.[5]
  • Atopic dermatitis is a life long disease with periods of waxing and waning eczematous skin lesions.[6]

Complications

Prognosis

References

  1. 1.0 1.1 Garmhausen D, Hagemann T, Bieber T, Dimitriou I, Fimmers R, Diepgen T, Novak N (April 2013). “Characterization of different courses of atopic dermatitis in adolescent and adult patients”. Allergy. 68 (4): 498–506. doi:10.1111/all.12112. PMID 23452057.
  2. Burr ML, Dunstan FD, Hand S, Ingram JR, Jones KP (June 2013). “The natural history of eczema from birth to adult life: a cohort study”. Br. J. Dermatol. 168 (6): 1339–42. doi:10.1111/bjd.12216. PMID 23301666.
  3. Garmhausen D, Hagemann T, Bieber T, Dimitriou I, Fimmers R, Diepgen T, Novak N (April 2013). “Characterization of different courses of atopic dermatitis in adolescent and adult patients”. Allergy. 68 (4): 498–506. doi:10.1111/all.12112. PMID 23452057.
  4. Garmhausen D, Hagemann T, Bieber T, Dimitriou I, Fimmers R, Diepgen T, Novak N (April 2013). “Characterization of different courses of atopic dermatitis in adolescent and adult patients”. Allergy. 68 (4): 498–506. doi:10.1111/all.12112. PMID 23452057.
  5. Spergel JM (August 2010). “From atopic dermatitis to asthma: the atopic march”. Ann. Allergy Asthma Immunol. 105 (2): 99–106, quiz 107–9, 117. doi:10.1016/j.anai.2009.10.002. PMID 20674819.
  6. Margolis JS, Abuabara K, Bilker W, Hoffstad O, Margolis DJ (June 2014). “Persistence of mild to moderate atopic dermatitis”. JAMA Dermatol. 150 (6): 593–600. doi:10.1001/jamadermatol.2013.10271. PMC 4352328. PMID 24696036.
  7. Matiz C, Tom WL, Eichenfield LF, Pong A, Friedlander SF (2011). “Children with atopic dermatitis appear less likely to be infected with community acquired methicillin-resistant Staphylococcus aureus: the San Diego experience”. Pediatr Dermatol. 28 (1): 6–11. doi:10.1111/j.1525-1470.2010.01293.x. PMID 21070347.
  8. 8.0 8.1 Ständer, Sonja; Ropper, Allan H. (2021). “Atopic Dermatitis”. New England Journal of Medicine. 384 (12): 1136–1143. doi:10.1056/NEJMra2023911. ISSN 0028-4793.
  9. Chen JJ, Applebaum DS, Sun GS, Pflugfelder SC (March 2014). “Atopic keratoconjunctivitis: A review”. J. Am. Acad. Dermatol. 70 (3): 569–75. doi:10.1016/j.jaad.2013.10.036. PMID 24342754.
  10. Pattnaik L, Acharya L (May 2015). “A comprehensive review on vernal keratoconjunctivitis with emphasis on proteomics”. Life Sci. 128: 47–54. doi:10.1016/j.lfs.2015.01.040. PMID 25744396.
  11. Illi S, von Mutius E, Lau S, Nickel R, Grüber C, Niggemann B, Wahn U (May 2004). “The natural course of atopic dermatitis from birth to age 7 years and the association with asthma”. J. Allergy Clin. Immunol. 113 (5): 925–31. doi:10.1016/j.jaci.2004.01.778. PMID 15131576.
  12. Illi S, von Mutius E, Lau S, Nickel R, Grüber C, Niggemann B, Wahn U (May 2004). “The natural course of atopic dermatitis from birth to age 7 years and the association with asthma”. J. Allergy Clin. Immunol. 113 (5): 925–31. doi:10.1016/j.jaci.2004.01.778. PMID 15131576.
Diagnosis

Diagnosis

History and Symptoms | Physical Examination | Laboratory Findings | Other diagnostic studies

Treatment

Treatment

Medical therapy | Primary prevention | Secondary prevention | Financial costs | Future therapies

Case Studies

Case Studies

Case #1

Related Chapters
External Links

Template:WikiDoc Sources

Looking for the patient version?

Back to the patient-friendly article

© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH